In This Issue
ACR Announcements
Issue Information
Clinical Connections
Review
Rheumatoid Arthritis and Risk of Malignant Lymphoma
Peficitinib, a JAK Inhibitor, in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate
Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities
Brief Report
Brief Report
Phenome‐Wide Association Study of Autoantibodies to Citrullinated and Noncitrullinated Epitopes in Rheumatoid Arthritis
The Transcriptional Coactivator Bob1 Is Associated With Pathologic B Cell Responses in Autoimmune Tissue Inflammation
Long‐Term Safety and Efficacy of Fulranumab in Patients With Moderate‐to‐Severe Osteoarthritis Pain
Discovery of T Cell Receptor β Motifs Specific to HLA–B27–Positive Ankylosing Spondylitis by Deep Repertoire Sequence Analysis
Brief Report
Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus
Expression of Cyclic GMP‐AMP Synthase in Patients With Systemic Lupus Erythematosus
Brief Report
VISTA Deficiency Accelerates the Development of Fatal Murine Lupus Nephritis
Ultraviolet B Irradiation Causes Stimulator of Interferon Genes–Dependent Production of Protective Type I Interferon in Mouse Skin by Recruited Inflammatory Monocytes
Clinical Images
A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis
A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Takayasu Arteritis
Anakinra for Colchicine‐Resistant Familial Mediterranean Fever
Middle Initial Omitted From Author Name in the Article by Felson et al (Arthritis Rheumatol, February 2017)
Reanalysis of the Multi‐Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic‐Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study
Limited Value of the Multi‐Biomarker Disease Activity Assay Compared to the Routine Assessment of Patient Index Data 3 (RAPID3) Score in the Prognosis of Important Clinical Outcomes in Rheumatoid Arthritis
Reply
The Role of Omalizumab in Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg‐Strauss)
Biologic Therapy for Eosinophilic Granulomatosis With Polyangiitis (Churg‐Strauss)
Reply